These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 15785091)

  • 1. Development of hepatocellular carcinoma after interferon therapy in chronic hepatitis C. Is it possible to reduce the incidence by ribanirin and IFN combination therapy?
    Izumi N; Yasuhiro A; Kurosaki M; Onuki Y; Nishimura Y; Inoue K; Ueda K; Tsuchiya K; Nakanishi H; Uchihara M; Miyake S
    Intervirology; 2005; 48(1):59-63. PubMed ID: 15785091
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A sustained virological response to interferon or interferon/ribavirin reduces hepatocellular carcinoma and improves survival in chronic hepatitis C: a nationwide, multicentre study in Taiwan.
    Yu ML; Lin SM; Chuang WL; Dai CY; Wang JH; Lu SN; Sheen IS; Chang WY; Lee CM; Liaw YF
    Antivir Ther; 2006; 11(8):985-94. PubMed ID: 17302368
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduced risk of hepatocellular carcinoma after interferon therapy in aged patients with chronic hepatitis C is limited to sustained virological responders.
    Imai Y; Tamura S; Tanaka H; Hiramatsu N; Kiso S; Doi Y; Inada M; Nagase T; Kitada T; Imanaka K; Fukuda K; Takehara T; Kasahara A; Hayashi N
    J Viral Hepat; 2010 Mar; 17(3):185-91. PubMed ID: 19709362
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk factors for development of hepatocellular carcinoma in patients with chronic hepatitis C after sustained response to interferon.
    Ikeda M; Fujiyama S; Tanaka M; Sata M; Ide T; Yatsuhashi H; Watanabe H
    J Gastroenterol; 2005 Feb; 40(2):148-56. PubMed ID: 15770398
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term outcome after interferon therapy in elderly patients with chronic hepatitis C.
    Arase Y; Ikeda K; Suzuki F; Suzuki Y; Saitoh S; Kobayashi M; Akuta N; Someya T; Koyama R; Hosaka T; Sezaki H; Kobayashi M; Kumada H
    Intervirology; 2007; 50(1):16-23. PubMed ID: 17164553
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined interferon and ribavirin therapy for chronic hepatitis C in Taiwan.
    Lai MY
    Intervirology; 2006; 49(1-2):91-5. PubMed ID: 16166795
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Data mining model using simple and readily available factors could identify patients at high risk for hepatocellular carcinoma in chronic hepatitis C.
    Kurosaki M; Hiramatsu N; Sakamoto M; Suzuki Y; Iwasaki M; Tamori A; Matsuura K; Kakinuma S; Sugauchi F; Sakamoto N; Nakagawa M; Izumi N
    J Hepatol; 2012 Mar; 56(3):602-8. PubMed ID: 22027574
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of hepatocellular carcinoma in patients with chronic hepatitis C who had a sustained virological response to interferon therapy: a multicenter, retrospective cohort study of 1124 patients.
    Kobayashi S; Takeda T; Enomoto M; Tamori A; Kawada N; Habu D; Sakaguchi H; Kuroda T; Kioka K; Kim SR; Kanno T; Ueda T; Hirano M; Fujimoto S; Jomura H; Nishiguchi S; Seki S
    Liver Int; 2007 Mar; 27(2):186-91. PubMed ID: 17311612
    [TBL] [Abstract][Full Text] [Related]  

  • 9. α-fetoprotein levels after interferon therapy and risk of hepatocarcinogenesis in chronic hepatitis C.
    Asahina Y; Tsuchiya K; Nishimura T; Muraoka M; Suzuki Y; Tamaki N; Yasui Y; Hosokawa T; Ueda K; Nakanishi H; Itakura J; Takahashi Y; Kurosaki M; Enomoto N; Nakagawa M; Kakinuma S; Watanabe M; Izumi N
    Hepatology; 2013 Oct; 58(4):1253-62. PubMed ID: 23564522
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Decreased risk of hepatocellular carcinoma in patients with chronic hepatitis C whose serum alanine aminotransferase levels became less than twice the upper limit of normal following interferon therapy.
    Moriyama M; Matsumura H; Aoki H; Shimizu T; Yamagami H; Shioda A; Kaneko M; Goto I; Tanaka N; Arakawa Y
    Liver Int; 2005 Feb; 25(1):85-90. PubMed ID: 15698403
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of interferon on incidence of hepatocellular carcinoma in patients with chronic hepatitis C.
    Soga K; Shibasaki K; Aoyagi Y
    Hepatogastroenterology; 2005; 52(64):1154-8. PubMed ID: 16001651
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term cohort study of chronic hepatitis C according to interferon efficacy.
    Maruoka D; Imazeki F; Arai M; Kanda T; Fujiwara K; Yokosuka O
    J Gastroenterol Hepatol; 2012 Feb; 27(2):291-9. PubMed ID: 21793911
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: A long-term observation study of 1,643 patients using statistical bias correction with proportional hazard analysis.
    Ikeda K; Saitoh S; Arase Y; Chayama K; Suzuki Y; Kobayashi M; Tsubota A; Nakamura I; Murashima N; Kumada H; Kawanishi M
    Hepatology; 1999 Apr; 29(4):1124-30. PubMed ID: 10094956
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination of interferon and ribavirin in chronic hepatitis C: re-treatment of nonresponders to interferon.
    Di Bisceglie AM; Thompson J; Smith-Wilkaitis N; Brunt EM; Bacon BR
    Hepatology; 2001 Mar; 33(3):704-7. PubMed ID: 11230751
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel predictive score for hepatocellular carcinoma development in patients with chronic hepatitis C after sustained response to pegylated interferon and ribavirin combination therapy.
    Chang KC; Hung CH; Lu SN; Wang JH; Lee CM; Chen CH; Yen MF; Lin SC; Yen YH; Tsai MC; Tseng PL; Hu TH
    J Antimicrob Chemother; 2012 Nov; 67(11):2766-72. PubMed ID: 22899800
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prolonged-interferon therapy reduces hepatocarcinogenesis in aged-patients with chronic hepatitis C.
    Arase Y; Ikeda K; Suzuki F; Suzuki Y; Kobayashi M; Akuta N; Hosaka T; Sezaki H; Yatsuji H; Kawamura Y; Kobayashi M; Kumada H
    J Med Virol; 2007 Aug; 79(8):1095-102. PubMed ID: 17597485
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of factors affecting the appearance of hepatocellular carcinoma in patients with chronic hepatitis C. A long term follow-up study after histologic diagnosis.
    Aizawa Y; Shibamoto Y; Takagi I; Zeniya M; Toda G
    Cancer; 2000 Jul; 89(1):53-9. PubMed ID: 10897000
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chronic hepatitis C virus infection in renal transplant: treatment and outcome.
    Sharma RK; Bansal SB; Gupta A; Gulati S; Kumar A; Prasad N
    Clin Transplant; 2006; 20(6):677-83. PubMed ID: 17100715
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of type 2 diabetes on risk for malignancies includes hepatocellular carcinoma in chronic hepatitis C.
    Arase Y; Kobayashi M; Suzuki F; Suzuki Y; Kawamura Y; Akuta N; Kobayashi M; Sezaki H; Saito S; Hosaka T; Ikeda K; Kumada H; Kobayashi T
    Hepatology; 2013 Mar; 57(3):964-73. PubMed ID: 22991257
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interferon therapy for 2 years or longer reduces the incidence of hepatocarcinogenesis in patients with chronic hepatitis C viral infection.
    Arase Y; Ikeda K; Tsubota A; Suzuki F; Suzuki Y; Saitoh S; Kobayashi M; Akuta N; Someya T; Hosaka T; Sezaki H; Kobayashi M; Kumada H
    Intervirology; 2004; 47(6):355-61. PubMed ID: 15564748
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.